Agreed Gary. A BO or partnership most certainly is on the table, as the chance of NWBO commercializing the treatment, at least on their own, is next to zero. To your point, timing is key here, I think there needs to be additional de-risking in the form of approval from the FDA specifically, at least for the BO. MHRA approval is great, but does not guarantee an FDA approval, and that's really what matters. Like you said, there could be plans right now though, to partner with big pharma in getting this through approval process with a BO after approval. My 2 cents based on launching drugs for big pharma.
Market Data 
Markets 
